Condition: Metastatic Breast Cancer · Leptomeningeal Disease · Sponsor: Wake Forest University Health Sciences
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
This description comes directly from the study's public registry record.
Sara Cox · 336-713-7748 · Sara.Cox@advocatehealth.org
Strowd Roy, MD · rstrowd@wakehealth.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Siteman Cancer Center- Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Active Not Recruiting |
| Comprehensive Cancer Center at Wake Forest University (CCCWFU) | Winston-Salem, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02422641